NBI 5788

an altered peptide ligand (APL)

Also Known As:

83-Ala-84-Lys-89-Leu-91-Ala-MBP(83-99); NBI-5788; myelin basic protein (83-99), Ala(83)-Lys(84)-Leu(89)-Ala(91)-; myelin basic protein (83-99), alanyl(83)-lysyl(84)-leucyl(89)-alanyl(91)-

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Myelin Proteins: 746
      - Myelin Basic Protein: 2422
        NBI 5788: 2
  - Nerve Tissue Proteins: 2
    - Myelin Proteins: 746
      - Myelin Basic Protein: 2422
        NBI 5788: 2
- Peptides: 82426
  - Peptide Fragments: 373
    - NBI 5788: 2

Experts

1.	Darlington, Cynthia L: 1 article (07/2005)
2.	Antel, J P: 1 article (11/2000)
3.	Conlon, P J: 1 article (11/2000)
4.	Crowe, P D: 1 article (11/2000)
5.	Qin, Y: 1 article (11/2000)

Related Diseases

Multiple Sclerosis

11/01/2000 - "NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients."
07/01/2005 - "Neurocrine Biosciences is developing NBI-5788, an analog of an immunodominant epitope of myelin basic protein for the potential intravenous treatment of multiple sclerosis. "
11/01/2000 - "We assessed the immune response induced in multiple sclerosis (MS) patients who had received NBI-5788, an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP) (5, 10, or 20 mg subcutaneously weekly for 4 weeks). "

Related Drugs and Biologics

1.	Immunodominant Epitopes
2.	Myelin Basic Protein
3.	Peptides (Polypeptides)
4.	Ligands